US/UK/Canada

Share

About Us

Klox Technologies Inc. is a private biomedical technology innovator, advancing the development and commercialization of its flagship fluorescent light energy generating technology within regenerative medicine. Klox has developed franchises in wound care, dermatology, animal health and oral health.

Links

Quotes

These new findings are a milestone for Kleresca® as they strongly support our current range of products including FLE for acne, rosacea and skin rejuvenation and provide strong hints towards new therapeutic areas for Kleresca®
Kleresca® General Manager Mr. Mikkel Schoedt
Kleresca® FLE technology strengthens the Laser Clinics Australia portfolio and will contribute to the continued growth of our business by giving us a competitive lead
Anthea Muir, CEO of Laser Clinics Australia
We are excited to have secured the MDSAP certification as it gears the company for further expansion into key markets. It is essential to have the basics in place and take the right steps at the right time. So during 2019, we will focus on investigating our operational options for entering the US market
General Manager Mikkel Schoedt
This research project focusing on FLE in dermatology opens up for whole new perspectives within immunology and we are excited to be part of it.
Prof. Dr. Søren Skov, University of Copenhagen
sk:n offer a wide range of dermatology and aesthetic treatments across our growing network of clinics. The partnership with Kleresca® further enhances our treatment portfolio with a new and innovative treatment we’re confident our clients are going to love.
Lisa Mason-Poyner, Director of Medical Services at sk:n clinics
This is a great treatment to add to the Kleresca® product portfolio and it offers us potential in all the markets we serve. The rosacea treatment will bolster our profile in therapeutic aesthetics and further define our footprint in the market
Mr. Mikkel Schoedt, General Manager of Kleresca®
The CE mark approval is a significant accomplishment for Kleresca® as it is based on a quality management system that we have tailored to our business from scratch securing a high degree of flexibility and agility in our day to day work while still being compliant. This enables us to continue to grow in a rapidly changing market”
Mr. Mikkel Schoedt, General Manager of Kleresca®
Pick a time period -
Tags ( Active)

Klox Technologies Inc. Files a De Novo Classification Request with the U.S. Food and Drug Administration

LAVAL, Quebec, FEBRUARY 4, 2020 -- Klox Technologies, Inc. (‘Klox’), a regenerative medicine company focused on the development of its proprietary FLE biomodulation platform, today announced that it has filed a De Novo Classification Request with the US FDA for its LumiHeal System following receipt of device designation in late 2019.“This significant milestone represents Klox’s commitment to work with the US FDA and CDRH to deliver an innovative treatment modality for healthcare practitioners and patients alike within wound care” said Carlo Bellini, President of Klox. “We are currently in

FDA Grants Device Designation Status for Klox’s LumiHeal System

LAVAL, Quebec, DECEMBER 12, 2019 -- Klox Technologies Inc. (‘Klox’) a regenerative medicine company developing and commercializing its proprietary fluorescent light energy generating platform within dermatology, wound care, and animal health, today announced, following remitting a Request for Designation, that the US Food & Drug Administration’s Office of Combination Products has given the LumiHeal System Device designation and will be reviewed and regulated by the Center for Devices and Radiological Health (CDRH).“This exciting milestone paves the way for Klox to address the single largest

Klox Technologies Inc. announces the appointment of Mr. Domenic Serafino and Dr. Richard Markoff to its board of directors

LAVAL, Quebec, October 8th, 2019 - Klox Technologies Inc. a regenerative medicine company focused on the development and commercialization of its proprietary fluorescent light energy biomodulation System (‘FB System’) in dermatology, wound care, and animal health, today announced it has appointed two new members to its board of directors.“Domenic’s and Richard’s expertise and history of execution will be instrumental in Klox’s commitment to building a best in class regenerative medicine company,” said Carlo Bellini, President of Klox. “We are pleased to welcome them to the Klox board of

Klox Technologies Inc. Announces Completion of the Acquisition of FB Dermatology

LAVAL, Quebec, October 04, 2019 -- Klox Technologies Inc. (‘Klox’) a regenerative medicine company focused on the development and commercialization of Fluorescent light energy Biomodulation Systems (‘FB System’) for applications in dermatology, wound care, and animal health, today announced it has completed the acquisition of FB Dermatology, a specialized dermatology company commercializing Kleresca® for the treatment acne, rosacea and skin rejuvenation.“We continue to be impressed with FB Dermatology’s ability to successfully gain commercial traction in multiple territories with the

Kleresca® strengthens scientific proof of fluorescent light energy (FLE) in new study

In a recent, peer-reviewed study, Kleresca® presents documentation that its unique FLE technology is able to reduce inflammation in the skin, enhance collagen production, and encourage the development of new blood vessels.The study investigated the cellular mode of action of FLE (fluorescent light energy) on skin and immune cells and combined clinical results with laboratory studies. This approach offered a unique opportunity to provide scientific answers to specific clinical questions. The study results show how FLE reduces inflammation in the skin, enhances collagen production, and

Kleresca® announces strategic partnership with Laser Clinics Australia

Laser Clinics Australia, Australia’s largest retail aesthetics clinics chain and Kleresca®, an innovative Danish/Irish med-tech company focusing on fluorescent light energy (FLE) in skin treatments have formed a strategic partnership whereby the Kleresca® FLE technology will be made available to the LCA customer base in Australia.The partnership makes gentle treatments that stimulate the skin’s own repair mechanisms available to patients with both therapeutic and aesthetic needs in more than 100 clinics across Australia covering all states and territories. With launch in New Zealand planned

Kleresca® achieves MDSAP certification

Ballerup, Denmark, December 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, has been certified according to The Medical Device Single Audit Program (MDSAP).Audited by the National Standards Authority of Ireland (NSAI), Kleresca® has been certified to be compliant with the standard and regulatory requirements for the medical device markets of Australia and Canada. With minor additional audits and approvals, the certification will also apply to Brazil, Japan and the United States. The MDSAP

Kleresca® employs industrial postdoc researcher to investigate impact of fluorescent light energy (FLE) on human immune system

Ballerup, Denmark, November 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, has strengthened its research activities by employing an industrial postdoc to investigate the impact of FLE on skin macrophages.Dr. Maiken Mellergaard, PhD in Immunology and Infectious Diseases, has been employed as industrial postdoc by Kleresca® in collaboration with University of Copenhagen (UCPH) to investigate how FLE impacts the macrophages in the human immune system. According to the Kleresca® General Manager,

sk:n clinics and Kleresca® announce national partnership making the Kleresca® biophotonic technology available across the UK

sk:n, the UK’s leading skincare clinic group specialising in medical aesthetics and dermatology in 49 award-winning clinics and Kleresca®, an innovative Danish/Irish med-tech company focusing on fluorescent light energy in skin treatments, have announced a comprehensive partnership making the innovative biophotonic technology of Kleresca® available nationwide in the UK.The partnership makes gentle treatments that stimulate the skin’s own healing processes with high efficacy and safety accessible to clients with both therapeutic and medical needs across the UK. There is growing consumer

Kleresca® releases unique biophotonic rosacea treatment

Ballerup, Denmark, August 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, today announced the release of a new treatment for rosacea.A new biophotonic treatment for rosacea is now available to patients through aesthetic clinics across 10 markets including Denmark, UK, France, Spain, Italy, Germany, Belgium, Norway, Australia and Switzerland.   The treatment is based on Kleresca®’s unique and patented biophotonic technology which uses fluorescent light energy to stimulate the skin’s own

Kleresca® receives CE mark approval for the next generation biophotonic system in dermatology

Ballerup, Denmark, August 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, today announced they have received CE mark approval for their technology platform.For Kleresca®, the CE mark approval is the foundation for future expansion in both Europe, US, Canada and Australia. It confirms that the product meets the requirements of the European Medical Device Directive. “The CE mark approval is a significant accomplishment for Kleresca® as it is based on a quality management system that we have

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media